Rare diseases
Investigational molecules
Locations
Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration
AustriaStudy of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration
AustriaStudy on Treating Neovascular Age-Related Macular Degeneration with Aflibercept, Ranibizumab, and Brolucizumab for Patients with Active Disease
AustriaStudy on Long-Term Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a Port Delivery System
AustriaFaricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia
FranceStudy on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema
AustriaStudy on the Use of SB11 Pre-Filled Syringe for Patients with Wet Age-Related Macular Degeneration, Macular Edema from Retinal Vein Occlusion, or Myopic Choroidal Neovascularization
PolandStudy on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration
CzechiaStudy on the Effects of RGX-314 Gene Therapy Compared to Aflibercept and Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration
FranceStudy of BP05 and Ranibizumab Efficacy and Safety in Patients with Wet Age-Related Macular Degeneration
LatviaStudy on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System
AustriaStudy on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients
AustriaTell us about your condition – we search every trial in Europe and connect you with the right site.
